GlassScriptPhysician profile
Joseph M Cherian
NPI 1629246707
$2,508.51
in general payments reported to CMS, 2019-2025
12 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $50.96 · 2021: $107 · 2022: $481 · 2023: $354 · 2024: $685 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,451.79 | 2021-2025 | Ffrct |
| Cvrx, INC. | $396.28 | 2023-2025 | Barostim Neo System |
| Abbott Laboratories | $205.55 | 2023-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Medtronic, INC. | $170.46 | 2025 | Symplicity G3 |
| Boston Scientific Corporation | $108.69 | 2019 | |
| Getinge USA Sales, LLC | $50.96 | 2020 | |
| Pfizer INC. | $49.95 | 2019 | |
| Daxor Corporation | $22.41 | 2024 | Bva-100 |
| Abiomed | $19.46 | 2024 | Impella |
| Cardiovascular Systems INC. | $17.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.77 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.